MX362582B - Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. - Google Patents
Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.Info
- Publication number
- MX362582B MX362582B MX2016000143A MX2016000143A MX362582B MX 362582 B MX362582 B MX 362582B MX 2016000143 A MX2016000143 A MX 2016000143A MX 2016000143 A MX2016000143 A MX 2016000143A MX 362582 B MX362582 B MX 362582B
- Authority
- MX
- Mexico
- Prior art keywords
- raf kinase
- urea compounds
- fused tricyclic
- dimer inhibitors
- tricyclic urea
- Prior art date
Links
- 150000003672 ureas Chemical class 0.000 title abstract 2
- 102000009929 raf Kinases Human genes 0.000 title 2
- 108010077182 raf Kinases Proteins 0.000 title 2
- 239000000539 dimer Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013078338 | 2013-06-28 | ||
| PCT/CN2014/080983 WO2014206343A1 (en) | 2013-06-28 | 2014-06-27 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000143A MX2016000143A (es) | 2016-06-15 |
| MX362582B true MX362582B (es) | 2019-01-24 |
Family
ID=52141106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000143A MX362582B (es) | 2013-06-28 | 2014-06-27 | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9670203B2 (enExample) |
| EP (1) | EP3013798B1 (enExample) |
| JP (4) | JP6380861B2 (enExample) |
| KR (1) | KR102272606B1 (enExample) |
| CN (2) | CN109369671B (enExample) |
| AU (1) | AU2014301816B2 (enExample) |
| BR (1) | BR112015032539B1 (enExample) |
| CA (1) | CA2916543C (enExample) |
| DK (1) | DK3013798T3 (enExample) |
| EA (1) | EA029412B1 (enExample) |
| ES (1) | ES2686821T3 (enExample) |
| IL (1) | IL242973A0 (enExample) |
| MX (1) | MX362582B (enExample) |
| NZ (1) | NZ716392A (enExample) |
| PT (1) | PT3013798T (enExample) |
| SG (1) | SG11201600147TA (enExample) |
| WO (1) | WO2014206343A1 (enExample) |
| ZA (1) | ZA201600513B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| PH12019502809B1 (en) | 2012-06-13 | 2024-04-24 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CA2916543C (en) * | 2013-06-28 | 2023-03-14 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| EP3386591B1 (en) | 2015-12-09 | 2020-06-24 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
| US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN112867716B (zh) | 2018-05-04 | 2024-09-13 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| US10584131B2 (en) | 2018-08-03 | 2020-03-10 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| CN111484490B (zh) * | 2019-01-25 | 2024-07-09 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021072028A1 (en) * | 2019-10-08 | 2021-04-15 | The Brigham And Women's Hospital, Inc. | Activators of heme regulated inhibitor kinase (hri) |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| HUE068185T2 (hu) | 2020-05-08 | 2024-12-28 | Halia Therapeutics Inc | NEK7-kináz inhibitorok |
| IL298760A (en) | 2020-06-05 | 2023-02-01 | Kinnate Biopharma Inc | Fibroblast growth factor receptor kinase inhibitors |
| CA3200386A1 (en) * | 2020-12-29 | 2022-07-07 | Seo Jung Han | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| JP2024513227A (ja) | 2021-04-05 | 2024-03-22 | ハリア・セラピューティクス・インコーポレイテッド | Ｎｅｋ７阻害剤 |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022226182A1 (en) | 2021-04-22 | 2022-10-27 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| JP2025519981A (ja) * | 2022-06-08 | 2025-06-30 | マップキュア，エルエルシー | Ｂ－ｒａｆ阻害剤によるがんの治療方法 |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| US20240122881A1 (en) * | 2022-10-14 | 2024-04-18 | Springworks Therapeutics, Inc. | Combination for use in treating cancers |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| WO2025079036A1 (en) | 2023-10-12 | 2025-04-17 | Beigene Switzerland Gmbh | Solid forms comprising a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100733D0 (sv) * | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| US7517992B2 (en) * | 2002-09-05 | 2009-04-14 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| WO2006066913A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| EP1957460A1 (en) * | 2005-12-08 | 2008-08-20 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| JP5271895B2 (ja) * | 2006-05-15 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗糖尿病性の二環式化合物 |
| US8067599B2 (en) | 2006-09-06 | 2011-11-29 | Hoffman-La Roche Inc. | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| CA2695004C (en) | 2007-07-17 | 2016-01-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| JP5806239B2 (ja) | 2010-01-27 | 2015-11-10 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾールのスルホンアミド誘導体 |
| US9273046B2 (en) | 2011-12-31 | 2016-03-01 | Beigene, Ltd. | Fused tricyclic compounds as Raf kinase inhibitors |
| US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| CA2916543C (en) | 2013-06-28 | 2023-03-14 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
-
2014
- 2014-06-27 CA CA2916543A patent/CA2916543C/en active Active
- 2014-06-27 US US14/901,634 patent/US9670203B2/en active Active
- 2014-06-27 CN CN201811172580.7A patent/CN109369671B/zh active Active
- 2014-06-27 EP EP14818636.4A patent/EP3013798B1/en active Active
- 2014-06-27 PT PT14818636T patent/PT3013798T/pt unknown
- 2014-06-27 AU AU2014301816A patent/AU2014301816B2/en active Active
- 2014-06-27 EA EA201690098A patent/EA029412B1/ru not_active IP Right Cessation
- 2014-06-27 MX MX2016000143A patent/MX362582B/es active IP Right Grant
- 2014-06-27 JP JP2016522232A patent/JP6380861B2/ja active Active
- 2014-06-27 ES ES14818636.4T patent/ES2686821T3/es active Active
- 2014-06-27 BR BR112015032539-4A patent/BR112015032539B1/pt active IP Right Grant
- 2014-06-27 CN CN201480037041.6A patent/CN105452223B/zh active Active
- 2014-06-27 SG SG11201600147TA patent/SG11201600147TA/en unknown
- 2014-06-27 NZ NZ716392A patent/NZ716392A/en unknown
- 2014-06-27 DK DK14818636.4T patent/DK3013798T3/en active
- 2014-06-27 KR KR1020167001854A patent/KR102272606B1/ko active Active
- 2014-06-27 WO PCT/CN2014/080983 patent/WO2014206343A1/en not_active Ceased
-
2015
- 2015-12-20 IL IL242973A patent/IL242973A0/en active IP Right Grant
-
2016
- 2016-01-22 ZA ZA2016/00513A patent/ZA201600513B/en unknown
-
2017
- 2017-04-28 US US15/581,728 patent/US9920055B2/en active Active
-
2018
- 2018-01-29 US US15/882,067 patent/US10208038B2/en active Active
- 2018-07-19 JP JP2018135807A patent/JP6707584B2/ja active Active
-
2019
- 2019-01-09 US US16/243,301 patent/US10562899B2/en active Active
-
2020
- 2020-05-20 JP JP2020088185A patent/JP6889311B2/ja active Active
-
2021
- 2021-05-20 JP JP2021085486A patent/JP7207629B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000143A (es) | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. | |
| MX2014007829A (es) | Compuestos triciclicos fusionados como inhibidores de cinasa raf. | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| MY184733A (en) | Pyrimidine fgfr4 inhibitors | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
| ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
| MX2015015421A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| MX2015015417A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| LT3623362T (lt) | Trąšų mišinys, kurio sudėtyje yra nitrifikacijos inhibitoriaus | |
| UA117011C2 (uk) | Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| LT3386991T (lt) | Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai | |
| CR20150133A (es) | Amino-quinolinas como inhibidores de cinasa | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| EA201690716A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ | |
| BR112014030720A8 (pt) | composto, composição farmacêutica e usos de inibidores de fbx03 | |
| MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |